[Mitoxantrone - an anthraquinone antibiotic with antitumor activity applied for the treatment of multiple sclerosis]

Area of Science:

• Immunology
• Neuroscience
• Pharmacology

Background:

• Mitoxantrone is an antineoplastic agent used for secondary progressive multiple sclerosis (MS).
• It functions by inducing cell death in antigen-presenting cells.
• Its mechanism involves both short-term cell lysis and long-term programmed cell death.

Purpose of the Study:

• To investigate the cytotoxic effects of mitoxantrone on immune cells implicated in MS.
• To evaluate the clinical outcomes and side effects of mitoxantrone treatment in MS patients.
• To highlight the need for novel therapeutic agents with reduced toxicity.

Main Methods:

• Review of scientific literature on mitoxantrone's cellular mechanisms.
• Analysis of clinical data from hospital treatments of multiple sclerosis patients.

Main Results:

• Mitoxantrone exhibits cytotoxic effects on immune cells contributing to axonal damage in MS.
• Clinical data reveal significant cardiotoxicity, including decreased left ventricular ejection fraction and increased risk of heart failure.
• Mitoxantrone metabolism generates reactive oxygen species, contributing to toxicity in healthy tissues.

Conclusions:

• Mitoxantrone's benefits in MS are counterbalanced by significant immune and cardiac toxicity.
• The drug's mechanism involves immune cell modulation and potential damage to cardiac tissue.
• Developing less toxic alternatives is crucial for managing multiple sclerosis effectively.